Heavier, Longer, Different: Your Period on a GLP-1

The question underneath the famous question

The best-known cycle story on this drug is whether a period stops or comes back, and we have already told it: weight loss can restart ovulation, ovulation returns before a bleed does, and a woman who assumed she could not conceive easily may find otherwise.

This is the other question, the one asked by women whose periods never went anywhere. It arrives at month four, in a tone of mild annoyance rather than alarm: my cycle is still here, it is just different. Heavier. Longer. Or three days shorter and considerably more unpleasant. And the internet, which has an enormous amount to say about restored fertility, has almost nothing to say about flow.

Neither do the labels. Read the current prescribing information for Wegovy and for Zepbound and the word menstrual does not appear once in either document¹. So nothing here is a listed effect of the medication. What follows is the mechanism, the little evidence that exists, and where the boundary sits between an annoyance and an appointment.

Where a heavy period comes from in the first place

The useful frame is not "what is the drug doing" but "what was my weight already doing".

Adipose tissue is hormonally active: it converts androgens to oestrogen, and it drives the insulin resistance and lowered sex-hormone-binding globulin that push a cycle toward anovulation. A review of the effects of obesity on the menstrual cycle sets out the consequences in a line — greater menstrual irregularity, infrequent or absent periods, and heavy menstrual bleeding, alongside higher rates of premenstrual syndrome and premenstrual dysphoric disorder². The mechanism behind heavy bleeding specifically is that a cycle without ovulation is a cycle without the progesterone that would normally hold the lining in check; it builds, and then it sheds unpredictably and at length.

That review's evidence base sits mostly in adolescents and young women, which is a real limitation to state. The adult data points the same direction. In the Study of Women's Health Across the Nation, self-recorded menstrual calendars from 963 women through the menopausal transition found that women with obesity had cycles one to five days longer than women without — and that the lengthening showed up at the long tail of the distribution rather than in the median³. Weight does not shift the average cycle. It stretches the outliers.

So a body that loses fifteen or twenty per cent of its weight is not having its cycle interfered with by a pen. It is losing the input that was distorting the cycle.

What the loss actually does to it

The direct evidence is thin, and almost all of it is in polycystic ovary syndrome, where the effect is largest and easiest to see.

A randomised, open-label trial in Chongqing assigned 100 overweight or obese women with PCOS to metformin alone or metformin plus weekly semaglutide for sixteen weeks. The combination group lost an average of 6.09 kg against 2.25 kg, with greater falls in testosterone and waist-to-hip ratio — and the women in the trial on combination therapy had higher rates of menstrual cycle recovery. Between weeks sixteen and forty, when everyone was back on metformin alone, the natural pregnancy rate in that group was 35% against 15%⁴.

Note what "recovery" means there, because it is the whole point of this section. A cycle that recovers is not simply a cycle that reappears. It is a cycle that has started ovulating again — which typically makes bleeding shorter, lighter and more predictable than the long anovulatory bleeds that preceded it. For a great many women, that is what the change at month four actually is, and it reads as improvement rather than side effect.

The women for whom it goes the other way — a cycle that becomes erratic or disappears under fast loss and low intake — are covered in the companion piece, because that is a story about the pace of loss rather than the shape of a period.

A period that changes on this medication is usually reporting on the weight, not on the drug. Which direction it moves depends on where you started.

PMS, which has exactly one useful study

Premenstrual symptoms are the complaint most likely to be dismissed, and the evidence for change is better than you would guess — although it is not from a GLP-1.

A case-control study followed 131 women with obesity and PMS, of whom 68 chose sleeve gastrectomy and 63 did not, scoring themselves on the Premenstrual Syndrome Screening Tool at baseline and three months. PMS improved in 57.35% of the surgical group against 25.40% of the controls, and the authors linked the improvement to changes in BMI, testosterone and oestradiol⁵.

That is weight loss by a different route, in a smaller and self-selected group, and it cannot be transplanted onto a pen without caveats. But it is a real, prospective signal that the premenstrual week is responsive to metabolic change — which is a better answer than the shrug most women get, and a reason to expect this to move rather than to assume it will not.

The contraception rule, stated exactly

This is the paragraph on this page most likely to change something, and it is precise in a way that matters.

Tirzepatide — Zepbound and Mounjaro — carries an instruction about oral contraception. The label advises patients using oral hormonal contraceptives to switch to a non-oral method, or add a barrier method, for four weeks after starting and for four weeks after each dose escalation, and states that hormonal contraceptives not administered orally should not be affected. The reason is delayed gastric emptying: after a single 5 mg dose given with a combined oral contraceptive, peak concentrations of ethinyl estradiol, norgestimate and norelgestromin fell 59%, 66% and 55%, with total exposure down about a fifth⁶.

Semaglutide does not carry that instruction. The word contraceptive appears in the Zepbound label eighteen times and in the Wegovy label not once¹. There is no equivalent finding behind it and no window to observe.

Put the two facts together and the risk is specific rather than general: a woman on the pill, on tirzepatide, in the weeks around a dose change — at the same time as an ovulatory cycle may be returning. The full version of that story, including which methods sidestep the problem entirely, is in our birth-control piece.

What is worth raising, and when

Most cycle change on this medication is unremarkable and settles as weight stabilises. Three things are not.

• Bleeding that is genuinely heavy — soaking through protection hourly, passing large clots, or lasting well beyond a week — is abnormal uterine bleeding whatever caused it. Joint practice guidance from the AAGL, ESGE and the Global Community on Hysteroscopy treats abnormal uterine bleeding as warranting histopathologic evaluation where intrauterine pathology is suspected, and that threshold does not move because you have started a new medication⁷.
• Bleeding that is not a period at all — between cycles, after sex, or at any point after menopause — belongs in a different conversation entirely, and it is covered separately. Do not wait it out.
• Premenstrual symptoms that have become severe rather than merely present — the week that now wrecks a marriage or a job — deserves a name and a plan, not an apology.

And a fourth thing that is not a symptom at all: if your cycle has become regular for the first time in years, that is information. It means something changed about ovulation, and it means the contraception question above is now live. The most useful sentence you can bring to the next appointment is not "my period is weird". It is "my cycle changed in this specific way, in this month, on this dose" — and, if you take the pill, "here is what I use."